Quantcast
Published On: Fri, Jun 6th, 2014

Eloctate, Antihemophilic Factor receives FDA approval for treatment of Hemophilia A

The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

Global Dispatch 200x119Eloctate is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures, and prevent or reduce the frequency of bleeding episodes (prophylaxis). Eloctate consists of the Coagulation Factor VIII molecule (historically known as Antihemophilic Factor) linked to a protein fragment, Fc, which is found in antibodies. This makes the product last longer in the patient’s blood.

“The approval of this product provides an additional therapeutic option for use in the care of patients with Hemophilia A,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

Hemophilia A is an inherited, sex-linked, blood clotting disorder, which primarily affects males, and is caused by defects in the Factor VIII gene. Hemophilia A affects 1 in every 5,000 males born in the United States. People with Hemophilia A can experience repeated episodes of serious bleeding, mainly into the joints, which can be severely damaged by the bleeding.

The safety and efficacy of Eloctate were evaluated in a clinical trial of 164 patients that compared the prophylactic treatment regimen to on-demand therapy. The trial demonstrated that Eloctate was effective in the treatment of bleeding episodes, in preventing or reducing bleeding and in the control of bleeding during and after surgical procedures. No safety concerns were identified in the trial.

Eloctate received orphan-drug designation for this use by the FDA because it is intended for treatment of a rare disease or condition.

Eloctate is manufactured by Biogen Idec, Inc., Cambridge, Mass.

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- The generic Dispatch designation, used primarily for press releases or syndicated content, but may be used for guest author requesting a generic nomenclature

Tags

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



Recent Posts

Chat and Meet apps for mobile

November 30, 2022, Comments Off on Chat and Meet apps for mobile

Addressing the Bias in the Grant Awards System

November 30, 2022, Comments Off on Addressing the Bias in the Grant Awards System
lab test research laboratory

Can Biological Research Be Conducted Successfully Online?

November 23, 2022, Comments Off on Can Biological Research Be Conducted Successfully Online?

What are the best ideas for Catholic gifts on your Christmas?

November 23, 2022, Comments Off on What are the best ideas for Catholic gifts on your Christmas?

Virtual Career Opportunities in the US Job Market for Internationals

November 16, 2022, Comments Off on Virtual Career Opportunities in the US Job Market for Internationals

Getting The Best Online Deals For A Car, Truck, Or SUV

November 14, 2022, Comments Off on Getting The Best Online Deals For A Car, Truck, Or SUV

Is Secularism or Cohabitation Affecting the Success of Your Marriage?

November 14, 2022, Comments Off on Is Secularism or Cohabitation Affecting the Success of Your Marriage?

How to Make Your Mobile Phone More Secure

November 14, 2022, Comments Off on How to Make Your Mobile Phone More Secure

Categories

Archives